Furthermore, by using public datasets that included a total of 684 breast cancer patients, we found that the expression of TG2 and IL-6 was correlated in breast cancer patients and that the combined high expression of TG2 and IL-6 was related to a poor DMFS outcome in breast cancer. This evidence concerns the gene IL6 and breast carcinoma.